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Abstract
Nowadays, increases in resistance of tumors to the current therapeutic agents have become a problematic issue. Therefore,
efforts to discover new anticancer compounds with high sensitivity of cancer cells are extending. Animal and laboratory
researches have shown that exogenous antioxidants are able to help prevent the free radical damage associated with the
development of cancer. However, researches in human beings have not demonstrated convincingly that taking antioxidants can
reduce the risk of developing cancer. Angiogenesis is also a natural condition that controls the formation of new blood vessels
from the available vessels. Today, it is believed that most of the cancers have angiogenesis potential and their growth, metastasis,
and invasion depend on angiogenesis. Several compounds with plant origin and with anti-angiogenic properties have been
identified. The aim of this study is to review recently published articles about anticancer drugs obtained from plants with anti-
oxidant and anti-angiogenesis properties.
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Plants are considered as important resources for researchers to
prove and develop new drugs. Generally, using plants in the
treatment of cancer has a long history and thus plants have been
primary resources for producing traditional drugs effective in
the treatment of cancer.1
After identifying new proteins that had important regulatory
effects on the development of the tumors cell cycle, research in iso-
lating molecules from plants and other natural organisms approved
that plants are important resources for synthesis inhibitors that have
potential to develop production of anticancer drugs.2
Moreover, researchers have reported a large number of plant
species that have been used in the treatment of cancer since
ancient times, and today, the tendency toward the use and eva-
luation of therapeutic effects of plants and their compounds as
potential anticancer drugs are increasing. So at the present time,
more than half of the used anticancer drugs are derived from nat-
ural resources like plants, microorganisms, and sea creatures.3
The mechanisms by which these drugs act on cancer cells are
mostly unclear. However, the role of oxidative stress in the
induction of cancer and antioxidants in the prevention and treat-
ment of cancer is obvious, and most plants are good sources of
antioxidants.4-8 Numerous studies have suggested that most can-
cers are diet related. Furthermore, the risks of most kinds of can-
cers can be reduced by dietary changes. In this regard, the studies
in different countries have suggested that the prevalence of can-
cer is less in people who eat higher amounts of fruits or vegeta-
bles that have antioxidant activity.9,10
There are more than 25 000 phytochemicals in different
plants that often have biological effects.11 Diets rich in herbal
resources provide necessary essential vitamins and minerals to
the body. The ability of the molecules present in medicinal
plants to bond therapeutic sites holds promise for achievement
of natural products and compounds from plants that are effec-
tive on cancer with low toxicity on healthy tissues.12
Angiogenesis is also a natural condition that controls the for-
mation of new blood vessels from the available vessels and has a
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crucial role in cancer development. This process, unlike cancer,
is the basis of several physiologic processes like embryonic
development, reproduction cycle, and wound healing.13
In fact, it is believed that most of the cancers have angiogen-
esis potential and their growth, metastasis, and invasion depend
on angiogenesis. Furthermore, the agents with anti-angiogenesis
activities have the potential to control cancer development.14
In this study, we aim to review present data on recently pub-
lished articles about the role of natural antioxidants and anti-
angiogenesis agents on cancer development.
The Role of Plant Antioxidants on Cancer
Free radicals, and in particular reactive oxygen species, are
formed naturally in the body when an atom or a molecule either
loses or gains an electron. Free radicals play an important role
in many normal cellular processes.15 However, at high concen-
trations, they can damage all major components of cells,
including proteins, DNA, and cell membranes. These damages
to cells, especially damage to DNA, play a crucial role in the
development of cancer.16 Moreover, some environmental tox-
ins, such as cigarette smoke, may contain larger amounts of
free radicals or stimulate the body’s cells to produce more free
radicals.16 Free radicals, other than cancer, are involved in a
wide variety of disorders, especially in degenerative diseases
such as neurological disorders,4,17 chronic inflammation,
and the generation of damage, particularly during ischemia/
reperfusion, diabetes,18,19 atherosclerosis,20,21 cardiovascular
diseases,22,23 and wound complications.24,25 These conditions
involve many changes, including alterations in the redox
state.26,27 Antioxidants, especially medicinal plants with
antioxidant activity, have the ability to counteract these condi-
tions.28,29 Various clinical and experimental studies have
demonstrated promising results for various conditions, espe-
cially for the treatment and prevention of life-threatening dis-
eases.30-33 These agents are also effective in inhibition of
toxic agents induced complications.8,34
The body makes some of the antioxidants that are called
endogenous antioxidants. However, the body relies on exogen-
ous sources of antioxidants for the rest of the antioxidants it
needs.35 A lot of medicinal plants have antioxidant activ-
ity24,32,33,36 and have shown promising results in cancer therapy.
Here we try to present the role of plants having antioxidant activ-
ity in cancer therapy.
In laboratory and preclinical studies in cancer prevention37
or immune system stimulation,38 promising results have been
achieved. However, whether or not taking dietary antioxidants
can prevent or reduce the risk of developing cancer in humans
is not clear. The cohort and case-control studies that have
investigated the use of dietary antioxidants in the risk of cancer
in humans have achieved mixed results. Due to inadequate
control for biases that might influence the results, observa-
tional studies must be viewed with caution. Randomized con-
trolled clinical trials are considered to provide more reliable
evidence of the harm or benefit of a health-related interven-
tion. However, the randomized controlled trials of antioxidant
supplementation for cancer prevention are inadequate to be
concluded. The results of these trials are summarized below.
The first trial was a large-scale randomized trial investigat-
ing the effect of antioxidants on cancer risk of healthy Chinese
people at increased risk of developing gastric and esophageal
cancers. The participants were randomly assigned to take a
combination of 50 mg selenium, 15 mg b-carotene, and
30 mg a-tocopherol per day for 5 years or no supplement. The
results of the study demonstrated that the risk of developing
gastric cancer and/or esophageal cancer was not affected by
antioxidant supplementation. However, people who took anti-
oxidants had lower rates of death due to gastric cancer, but not
due to esophageal cancer.39 In this study, 10 years after antiox-
idant supplementation ended, reduced risk of gastric cancer
death was no longer found for those who took antioxidants,
in comparison to those who did not.40
In a second trial, which was conducted in Finland, 5 to
8 years of consumption of a-tocopherol and/or b-carotene
could reduce the incidence of different cancers in middle-
aged male smokers. The initial results of the study showed
an increase in the incidence of lung cancer in the participants
who took 20 mg per day b-carotene supplementation.41 There
were no effects of a-tocopherol or b-carotene supplementa-
tion on the incidence of renal pelvis, bladder, ureter, pan-
creas, colorectal, kidney, pharyngeal, laryngeal, or esophageal
cancers.42
In a trial in the United States, daily supplementation with
b-carotene and vitamin A on people who were at high risk of
lung cancer due to having a history of smoking or exposure
to asbestos showed that daily supplementation with both
25 000 IU retinol and 15 mg b-carotene was associated with
increased lung cancer and increased death from all-cause mor-
tality.43 A later report in 2004 showed that the adverse effects
persisted up to 6 years after the consumption of these supple-
ments ended. However, the enhanced risks of all-cause mortal-
ity and lung cancer were no longer statistically significant.44
In another study in 1996, 50 mg b-carotene administration
every other day for 12 years had no effect on cancer mortality,
cancer incidence, and all-cause mortality among US male
subjects.45
Every other day administration of 50 mg b-carotene, 600 IU
vitamin E, and 100 mg aspirin has also had no benefit or the
incidence of cancer and cardiovascular diseases in US women
of over 45 years.46 In 2005, similar results were published for
vitamin E consumption.47
In a trial published in 2004, daily supplementation with 100
mg selenium, 20 mg zinc, 6 mg b-carotene, 30 mg vitamin E,
and 120 mg vitamin C, for a median of 7.5 years, had no effect
on the incidence of cardiovascular or cancer diseases or all-
cause mortality.48
In an international trial reported in 2005, no effect of daily
supplementation with 400 IU a-tocopherol, which was admi-
nistered for 7 years was seen in the incidence of major cardio-
vascular events—such as stroke, heart attack or death from
heart disease, cancer incidence or death from cancer in people
diagnosed with cardiovascular disease or diabetes.49
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The next trial was conducted in the United States, began in
2001 and was stopped in 2008. The trial investigated whether
daily supplementation with 200 mg selenium, 400 IU vitamin
E, or both would reduce the incidence of prostate cancer in
men over 50 years. The results showed that the use of these sup-
plements for a period of about 5.5 years did not affect the inci-
dence of prostate or other cancers.4 Updated findings, reported
in 2011, demonstrated that, following 1.5 years of supplements,
the cases of prostate cancer among men taking vitamin E alone
were 17% more compared to the placebo group.50 No increase
in prostate risk was observed for men assigned to take vitamin
E plus selenium or selenium alone compared with men
assigned to take a placebo.49
In a trial that was conducted in 2009, the use of 500 mg vita-
min C, 400 IU vitamin E, or a combination of the two, every
other day for a median of 7.6 years, did not reduce the inci-
dence of prostate cancer or other cancers, including leukemia,
melanoma, lymphoma, and cancers of the bladder, pancreas,
lung, colon, and rectum.52
The aforementioned randomized controlled clinical trials
did not show that dietary antioxidant supplements are bene-
ficial in primary cancer prevention. However, it is possible
that the lack of benefit in clinical studies can be related to
the effects of the tested antioxidants. They all were con-
sumed as purified chemicals and they might be opposed
when they are consumed in foods, which contain complex
mixtures of minerals, vitamins, and various antioxidants.
This acquire a more complete understanding of the antioxi-
dant content of individual foods, how the various antioxi-
dants interact with each other, and the factors that influence
the uptake and distribution of food-derived antioxidants in the
body. These are all active areas of ongoing cancer prevention
research.
Another question that might be raised is that whether
or not people already diagnosed with cancer should take
antioxidant supplements? A randomized controlled trial
reported that antioxidant supplements during cancer treat-
ment might alter the effectiveness or reduce the toxicity
of specific therapies.53 Other trials have reported mixed
results; some of them found that people who took antioxi-
dants during cancer therapy had worse outcomes, especially
if they were smokers.
Additional large randomized controlled studies are neces-
sary to provide clear evidence about the benefits or harms of
taking antioxidant supplements during cancer treatment. The
role of natural compounds with angiogenesis inhibitory activity
in cancer therapy.
Angiogenesis is a natural condition that controls the
formation of new blood vessels from the available vessels.
This process is the basis of several physiologic processes
like embryonic development, reproduction cycle, and wound
healing.13,54
In the natural formation of the new blood vessels, which is a
completely controlled process, endothelial cells receive stimu-
lator massage and secret special enzymes like matrix metallo-
proteinase and heparin that cause digestion of the extracellular
matrix and basal lamina and as a result strong connections
between endothelial cells are disjointed. When this process is
continued, endothelial cells can be created and as a result immi-
gration and reproduction are organized for forming new capil-
lary tubes. In many crucial states of diseases, the control of
angiogenesis is disturbed. When the cells of patients unnatu-
rally produce large amounts of angiogenesis factors like
endothelial cell growth factor (VEGF), fibroblastic growth
factor (FGF-2), and hepatocyte growth factor, these factors
overpass effects of the natural inhibitors like angiostatin, endo-
statin, and thrombospondin and thus excessive angiogenesis
occurs.
Generally, there are more than 70 other diseases like obe-
sity, rheumatoid arthritis, and asthma that are related to the
unnatural angiogenesis.55 Today, it is believed that most of the
cancers have angiogenesis potential and their growth, metasta-
sis, and invasion depend on angiogenesis.14
One of the first identified and isolated anti-angiogenic
agents was a natural compound, namely, Fumagillin, which
is an antibiotic secreted from the Aspergillus fumigatus fungi.33
Gradually, other different compounds with plant origin and
with anti-angiogenic properties were identified and even effec-
tive compounds of some of them were isolated. Now, different
research models are used to screen plants that have anti-
angiogenic activities.56 Results of studies show that foods,
especially those with plant origin, have the potential to prevent
one third of cancers.14 So consumption of a plant diet might
prevent development and improvement of chronic diseases
like malignant tumors whose development is associated with
angiogenesis.57 However, it has been suggested that single
anti-angiogenic factors have limited efficacy. Useful natural
products contain a range of complex organic chemicals that
may have synergic activity. Possibly, other than interacting
with multiple angiogenesis pathways, they also act on other
pathways like cell signaling and the apoptosis pathways or
influence collision between cancer cells and immunity system
and so inhibit angiogenesis.58
Some of the anti-angiogenic factors also have anticoagulant
activity that may decrease metastasis of tumor cells.59 In addi-
tion, other anti-angiogenic compounds have been identified
and isolated during the past years by conducting extensive
researches. Examples are isolation of the inhibitory compound,
camptothecin from Camptotheca acuminate in 1966, identifi-
cation and isolation of the angiogenesis-inhibiting compound
taxol from Taxus baccata plant in 1971, isolation of combretas-
tin from Combretum caffrum in 1987, and other studies in the
field of identification of anti-angiogenic properties of different
plants and their effective compounds.
It should be noted that different plants contain very active
compounds that some of them have properties effective on
angiogenesis. In fact, plants are complex chemical cocktails
with different properties. It means that not just one mechanism
of a plant acts on cancer in angiogenesis but may include sev-
eral mechanisms.
Some of reliable anticancer drugs obtained from plants with
anti-angiogenic properties are introduced below.
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Taxol
Researchers identified an extract made from the bark of the
Pacific yew tree with the scientific name Taxus brevifolia in
1962 that has anticancer properties. The active compound in
this extract was then identified in 1971and named taxol, which
is a complex diterpene (Figure 1).46 Thereafter, taxol was pro-
duced synthetically and used.
Taxol combats cancer cells that are multiplying by disrupt-
ing their microtubule skeleton. Results of studies done by
researchers have shown that taxol at low picomolar concentra-
tions inhibits angiogenesis by inhibiting VEGF production and
controlling the protein expression of the hypoxia-inducible fac-
tors. With regard to anti-angiogenic properties represented by
taxol, its antitumor properties are further confirmed. It has been
many years since the clinical application of taxol in the treat-
ment of cancer has been approved and it is yet used.59
Camptothecin
Camptothecin was first isolated from the Camptotheca acumi-
nate tree, a tree native to China, using the bioactivity-directed
fractionation technique (Figure 1). Camptothecin, as an antic-
ancer agent, was studied for 15 years and finally its exclusive
procedure to kill tumor cells was identified. This compound
traps topoisomerase I-DNA complexes, inhibits DNA replica-
tion, and leads to killing of cancer cells. The discovery of this
issue encouraged researchers to produce compounds similar to
camptothecin that have solubility in water and maintain their
anticancer activity. Finally, 2 compounds similar to camptothe-
cin, namely topotecan and trinotecan, were approved by the US
Food and Drug Administration in 1990 to be used to treat
colon, lung, and ovarian cancers.60 In 1999, it was shown that
camptothecin and topotecan inhibit the growth of the human
endothelial cells in vitro in a nontoxic manner and this inhibi-
tion continues up to 96 hours after the drug is stopped. They
also suggested that these 2 compounds are effective in angio-
genesis unlike the unspecific toxic drug, cisplatin or TNP-
470, in inhibition of angiogenesis. For this reason, in addition
to activities like killing tumors, camptothecin possibly pos-
sesses an indirect in vivo antitumor effect mediated through the
inhibition of angiogenesis.45
Combretastatin
Combretastatin is a microtubule-targeting agent found in the
bark of the African bush willow tree (Combretum caffrum),
identified in 1987 as an anticancer agent. More studies led to
the production of phosphate derivatives in aqueous solution
with more bioavailability. Vincent et al61 also suggested that
combretastatin A4 phosphate (CA4P; Figure 1) selectively tar-
gets endothelial cells and destroys new tumor vessels in mice
by disrupting the function of the junctional molecule of cad-
herin in endothelial cells. CA4P also increases permeability
of endothelial cells and inhibits immigration and formation
of capillary tube mainly through disrupting the signaling
pathway of E-cadherin/b-catenin/Akt that leads to the rapid
collapse of vessels and necrosis. This compound has a synergis-
tic effect with monoclonal anti–VE-cadherin antibody (when
this antibody is administered in low doses), which stops aggre-
gation of new vessels and so inhibits tumor growth. These find-
ings show that CA4P selectively induces regression of unstable
tumor neovessels and through disruption in the mentioned sig-
naling pathway.44,61
Some other natural compounds derived from plants with
anti-angiogenic activity are presented in Table 1.11
Some other plants and their derivatives that specifically
inhibit the vessels’ endothelia growth factor (VEGF) and have
antiangiogenic activity include the following: Artemisia
annua or Chinese wormwood (containing 95% artemisinin),
Vsicum album or European mistletoe (containing mistletoe
lectin III (ML3A), Curcuma longa or turmeric (containing
95% curcumin), Camellia sinensis or green tea (containing
95% phenols; 50% epigallocatechin), Vitis vinifera or grape
seed extract (containing 95% proanthocyanidins), Angelica
sinensis or Dong quai (containing 4-hydroxyderricin), Scutel-
laria baicalensis or Chinese skullcap (containing 95% baica-
lin and flavonoids), Polygonum cuspidatum or Japanese
knotweed (containing 20% resveratrol), Silybum marianum
or milk thistle (containing 80% silymarin), and magnolia seed
cones (containing 90% honokiol).
Some plant-derived compounds such as curcumin, gingiber,
bromelain, epigallocatechin-3 gallate, resveratrol, proantho-
cyanidin, and antioxidants present in plants (vitamins A, C,
E, selenium, zinc, carotenoids, flavonoids) have inhibitory
activity on the cyclooxygenase enzyme in the angiogenesis
pathway.11
Soybean Grains and Its Effective Compounds
The prevalence rate of breast and prostate cancer is very low in
Asian countries like Japan and China compared to European
countries and the United States of America. Studies show that
this important difference in the prevalence rate of cancer in dif-
ferent ethnic groups depends to some extent on eating habits. In
fact, one of the main differences in nutrition of these 3 types of
population is that Japanese and Chinese use food in their diet
that usually contain plant products including soybean. More-
over, Fotsis et al51 by studying the urine of persons who have
used large amounts of plant foods observed that urine of these
people contain isoflavones of soya and its metabolites, spe-
cially genistein, which inhibits proliferation of endothelial cells
of brain capillaries. Other studies also have suggested that pure
genistein has a strong dose-dependent inhibiting effect on the
proliferation of the endothelial cells. Genistein also inhibits
proliferation of other vessels’ endothelial cells like cells
derived from the bovine adrenal cortex and the aorta.52
Isoflavonoids are present mainly in vegetables. Soybean
grains and its products contain large amounts of isoflavonoids.
These observations and epidemiological and laboratory evi-
dence have shown that consumption of diets rich of soybean
products is associated with lower risk of getting cancer.
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Flavonoids like 3,4-dihydroxyflavone, 1,3-dihydroxyflavone,
fisetin, apigenin, and lutlin can inhibit in vitro angiogenesis
in the micromolar concentration range.62 Studies of researchers
have approved that genistein inhibits proliferation of VEGF-
induced endothelial cells and signaling molecules of tyrosine
phosphorylation in the micromolar range. Moreover, genistein
Figure 1. The chemical structure of factors affecting angiogenesis that have been obtained from medicinal drugs.
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inhibits effectively the mast cell chemotaxis as facilitator of
new vessels’ formation in response to some incentive factors
of angiogenesis. This compound can inhibit angiogenesis
through different methods like adjusting the activity of proteo-
lytic enzymes.62 Moreover, genistein suppress expression of
VEGF and FGF-2 and inhibits phosphorylation of the receptor
tyrosine kinase and activation of Akt. The mentioned com-
pound prevents activation of NF-kB that leads to apoptosis
even in cancer cells resistant to apoptosis.
Genistein as a phytostrogen also targets estrogen and andro-
gen signaling pathways in carcinogenesis and has antioxidant
properties. Generally, in vivo and in vitro studies have shown
that this isoflavone is a promising factor to treat or inhibit can-
cer. This peptide is called Kunitz trypsin inhibitor and its anti-
angiogenic property has been approved.63
Green Tea
Green tea, especially one of its compounds named epigalloca-
techin gallate (EGCG; Figure 1), inhibits angiogenesis signifi-
cantly. EGCG inhibits production of cytokine-induced IL-8,
inhibits AKt activation (induced by VEGF), and also prevents
phosphorylation of V-E cadherin in physiologic concentra-
tions. Findings also show that drinking green tea can be effec-
tive in inhibiting and treatment of angiogenesis-dependent
diseases like cancer and diabetic retinopathy.64
Red Grape
Red grape is a delicious fruit that contains a compound named
resveratrol (Figure 1). This compound can be found in peanut,
morus, and some other medicinal plants like Polygonum cuspi-
datum. Studies have suggested that this compound inhibits
angiogenesis when it is administered orally without important
side effects. This compound, as one of the most promising
chemical factors that inhibits cancer, has attracted excessive
attention in recent years. For this reason, there is possibility
to discover and identify more polyphenols in natural products
as compounds that lead to discovery of more strong synthetic
inhibitors of angiogenesis. Resveratrol may treat heart muscle
damage through inducing angiogenesis by VEGF and the
receptor tyrosine kinase FLK-1 (angiogenesis induction). How-
ever, recent inconsistent findings should be evaluated.65
Allium hirtifolium
This plant is one of the important species in Allium genus that
has been used in many countries including Iran as condiment
since the ancient times and has been used also in the traditional
treatment of cancer. This plant has known properties like effect
on hematologic indices, antioxidant potential, and antifungal
and antibacterial properties. Moreover, the study of its chemi-
cal components shows that it has many compounds like organo-
soulfurs and polyphenols that are very similar to compounds
available in other species in the same family. Aqueous extract
of Allium hirtifolium has a dose-dependent inhibitory effect on
the angiogenesis.66
Artemisia annua (Chinese Wormwood)
One of the compounds extracted from the Artemisia annua
plant is the active compound of artemisin that has anti-
angiogenic effects. This compound has been used in traditional
medicine as an antimalarial medication. Recently, researchers
have shown that this compound applies the toxic effect on
cancer cells via induction of apoptosis. Artesunate also is a
Table 1. Natural Compounds That Have Direct or Indirect Anti-Angiogenic Potential.
No. Plant Name Compound Possible Mechanism
1 Camellia sinensis (green tea) EGCG Abrogates VEGF signaling by interfering with formation of VEGF receptor-2
complex
2 Camptotheca acuminate Camptothecin Blocks topoisomerase I, inhibits EC proliferation and tube formation, decreases
HIF1a and VEGF expression
3 Combretum caffrum Combretastatin Inhibits tubulin assembly
4 Cordyceps militaris Unknown Inhibits FGF-2 expression in EC and MMP-expression in tumor cells
5 Ganoderma lucidum Polysaccharide, peptide Causes EC apoptosis by reducing Bcl-2 expression and increasing Bax
expression, decreases VEGF secretion from tumor cells
6 Glycine max (soybean) Genistein Suppresses VEGF and FGF-2 expression, inhibits receptor tyrosine kinase,
inhibits activation of NF-kB and Akt signaling pathways
7 Glycyrrhiza uralensis (liquorice) Isoliquiritin Inhibits tube formation
8 Panax ginseng Ginsenosides Rb1 Inhibits VEGF production by tumor cells
9 Sinomenium acutum Sinomenine G1-G0 arrest of ECs
10 Salvia miltiorrhiza (danshen) Cryptotanshinone G1-G0 arrest of ECs, apoptosis of ECs
11 Taxus brevifolia Taxol Disrupts microtubule cytoskeleton inhibits VEGF production, inhibits HIF-1a
protein
12 Tripterygium wilfordii Hook.f Triptolide Inhibits VEGF expression and secretion from ECs, inhibits COX-1, COX2, and
5-lipoxygenase, decreases transcription of the gene encoding inducible nitric
oxides synthase
13 Vinca rosea Vincristine Disrupts microtubule cytoskeleton, inhibits VEGF production
14 Vitis spp (grape) Resveratrol Disrupts Src-dependent VE cadherin tyrosine phosphorylation
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semisynthetic derivative of artemisinin that has anti-angiogenic
activity in a dose-dependent manner. Moreover, the in vivo
anti-angiogenic effect of artemisinin using transplantation of
cancer cells of human ovary in nude mice has been evaluated
and approved.67
Viscum album (European Mistletoe)
Viscum album, also known as iscador, often is used as an antic-
ancer agent. Laboratory studies show that compounds of this
plant via VEGF expression inhibit the angiogenesis and also
induce apoptosis in cancer cells. Using extract of this plant in
a mouse model leads to decreased lung metastasis and increase
in survival. Also, a clinical study performed on individuals with
different cancers indicates increase in their survival and long-
evity. Of course, more studies are required to specify different
aspects of therapeutic effects of this plant.67
Curcuma longa (Curcumin)
It is a compound that interacts with cancer cells in different lev-
els. Its antimetastatic effects are applied to some extent via a
decrease in expression of the matrix metalloproteinase enzyme
(MMP-2) and increase in expression of the tissue inhibitor of
metalloproteinase 1 (TIMP1). It should be recalled that the
mentioned enzymes have an important role in regulating angio-
genesis and tumor cell invasion. Studies have also suggested
that this compound inhibits transcription of angiogenesis fac-
tors VEGF and bFGF and also decreases production of nitric
oxide in endothelial cells that have an important role in the
development of angiogenesis and tumor growth. Other activi-
ties of this compound include binding to CD13 antibody
expressed by blood vessel components and inhibiting its activ-
ity, decreasing expression of VEGF and MMP-9, and inhibiting
EGF and VEGF receptors and also resisting intracellular sig-
naling pathway of tyrosine kinases.68,69
Scutellaria baicalensis (Chinese Skullcap)
Baicalin and baicalein are main derivations of the Chinese
skullcap plant. These 2 compounds are strong compounds that
decrease activity of VEGF, bFGF, 12-lipooxigenase, and also
matrix metalloproteinase. This plant is one of the known
Chinese plants that have shown activity against the develop-
ment of prostate cancer.70
Magnolia officinalis (Chinese Magnolia Tree)
Grains present in the fruit of Chinese magnolia contain sub-
stances that inhibit new blood vessels formation. The active
component of this compound is honokiol. This component can
decrease angiogenesis to some extent through regulating
expression of the endothelial cell growth factor derived from
placket and also transforming growth factor-b. Moreover, this
compound inhibits nitric oxide synthesis and tumor necrosis
factor expression. Studies using laboratory animals also have
shown that honokiol inhibits proliferation of blood vessels’
endothelial cells and so decreases tumor growth.71
Silybum marianum (Milk Thistle)
Silymarin and silibinin are polyphenolic flavonoids isolated
from fruits and seeds of Silybum marianum. Results obtained
from studies of researchers indicate that silymarin has strong
antitumor activity against types of tumors like ovary cancer via
decreasing expression of VEGF and EGFR.72,73
Ginkgo Biloba
An extract of this plant has anticancer effect having some prop-
erties like gene regulation and anti-angiogenic activities. An
extract of this plant contains about 25% flavonoids (ginkgo,
flavone glycosides) and about 5% terpenoids (ginkgolides and
bilobalides). Its most strong flavonoid is ginkgolide B. An
extract of this plant inhibits angiogenesis via decreasing the
VEGF expression.74
Plants Rich of Quercetin
Quercetin is a flavonoid compound that is found in apple,
onion, red grapes, black-berry, citrus, cherry, broccoli, and also
some of the species in the Allium family. This flavone inhibits
angiogenesis through different mechanisms like interacting
with cyclooxygenase-2 and 5-lipooxigenase, VEGFR enzymes,
HER-2 intracellular signaling pathways, and also nuclear tran-
scription protein NF-kB. Quercetin may enhance anticancer
effects of tamoxifen drug via its anti- angiogenic activity.75
Poria cocos
Studies have suggested that this extract inhibits placket accu-
mulation and apparently it has anti-angiogenic effect via
decreasing expression of the NF-kB.76
Panax ginseng
Lipophilic compounds of ginseng namely saponins and ginse-
nosids have anticancer activities including inhibiting angiogen-
esis and inducing apoptosis in tumor cells.77
Rabdosia rubescens Hara (Rabdosia)
Rabdosia has been used to treat cancer since ancient time. This
plant is one of the Chinese plants known as pc-spes and has
activity against the prostate cancer. This plant includes 2 diter-
penoids named ponicidin and oridonin that have significant
anti-angiogenic activity.78
Conclusions
Nowadays, increases in resistance of tumors to the current ther-
apeutic agents have become a problematic issue. Therefore, the
efforts of researchers to discover new anticancer compounds
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with high sensitivity of cancer cells are extending. Some of
cytotoxic drugs inhibit angiogenesis and have minimum toxi-
city. Studies on new plants will lead to discovery of new antic-
ancer drugs from plant sources and this success will be very
important.
Animal and laboratory researches have shown that exogen-
ous antioxidants are able to help prevent the free radical dam-
age associated with the development of cancer. However,
researches in humans have not demonstrated convincingly that
taking antioxidants can reduce the risk of developing cancer.
Furthermore, a wide variety of medicinal plants, including
Allium sativum, Stachys lavandulifolia, Artemisia abrotanum,
and Salvia officinalis have been shown to have antioxidant
activity.29,33,35,79-98 More important, it has been shown that
there is a correlation between antioxidant activity and antican-
cer effects of some medicinal plants such as garlic.38 If antiox-
idants are one of the main components of anticancer therapy,
then those plants that have antioxidant activity should all have
anticancer property. These may be worth examining.
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